Whistleblower Movement & NFSC ｜ 30 August 2021

Miles Guo: The artemisinin-based medicines discovered by Mrs. Tu Youyou are effective against the CCP virus. Mrs. Tu will become the hero who saves the human race!

Study reveals potential utility of artemisinin-based treatments against SARS-CoV-2

A bioRxiv paper found artemisinin-based treatment effective against two European SARS-CoV-2 strains, from Germany and Denmark, which the authors note are more closely related to most strains circulating worldwide than the Wuhan strain. [View more]

Breaking News: Artemisinin is the SARS-CoV-2 antidote

On 30 August local time, Mr. Miles Guo announced on his broadcast that Artemisinin, along with several other antidotes such as D-NAB, is a real solution for treating the CCP virus (SARS-CoV-2).

The CCP claimed a so-called “COVID cure breakthrough” after Mr. Miles Guo named Artemisinin as the antidote

On 1 September local time — just two days after Mr. Miles Guo revealed on his live broadcast that Artemisinin is one of the antidotes for the CCP virus — an article appeared on WeChat from Guangdong New South Group, the main maker of “artemisinin and piperaquine tablets”, headlined that the tablets had become popular worldwide overnight and the first choice for international students. Guangdong New South Group owns the majority of that product, and its board chairman, Zhu Layi, controls the artemisinin industry in Communist China. [View more]

Whistleblower Movement & NFSC ｜ 2020.02–2021.08

Miles Guo on the antidote of the CCP virus.

Whistleblower Movement & NFSC ｜ 30 August 2021

Miles Guo’s life-saving broadcast: D-NAB is the antidote to the CCP virus. The CCP has at least five types of antidotes, whose mechanism is antigen neutralisation.

The Wall Street Journal ｜ 28 July 2021

Why Is the FDA Attacking a Safe, Effective Drug?

Ivermectin is a promising COVID treatment and prophylaxis, but the agency is denigrating it.

By Alessandro Pedrini for Affaritaliani.it

Santin (Yale): surprising effectiveness of Ivermectin against COVID

Ivermectin is a low-cost, widely available drug that is effective across the phases of COVID-19: it has both an antiviral effect and a powerful anti-inflammatory effect — similar to cortisones, but not immunosuppressive. Its discovery earned the 2015 Nobel Prize in Medicine for William C. Campbell and Satoshi Ōmura. More than 40 completed clinical studies worldwide have shown it to be effective at reducing viraemia both early in the infection and during its later phase. [View more]

Hydroxychloroquine science | How HCQ works

Hydroxychloroquine sulfate has been approved for therapeutic use in the United States since 1955, and it appears on the WHO Model List of Essential Medicines — meaning it is considered efficient, safe and necessary.

In 2017 it ranked 128th on the United States’ list of the most commonly prescribed drugs, with more than five million prescriptions.

In January 2020 the Whistleblower Movement promoted HCQ on social media as a potential treatment for COVID-19.

Early treatment with HCQ: a country-based analysis

Many countries either adopted or declined early treatment with HCQ, effectively forming a large trial of 1.8 billion people in the treatment group and 663 million in the control group. As of 14 November 2020, an average of 138.5 per million had died in the treatment group versus 588.4 per million in the control group — a relative risk of 0.235. After adjustments, the figures became 267.8 and 889.8 per million, a relative risk of 0.30. The probability of an equal or lower relative risk arising from random group assignment is 0.030.

Adjusted deaths per million for countries using widespread early HCQ versus those that do not, with a prediction for the following 90 days. As of 14 November 2020, countries using early HCQ are predicted to have a 69.9% lower death rate after adjustments.